OR WAIT null SECS
© 2021 MJH Life Sciences and Rheumatology Network. All rights reserved.
© 2021 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
The move comes amid delays in FDA approvals for multiple JAK inhibitors for the treatment of rheumatic conditions.
The stigma surrounding gout has contributed to the general unease patients have about their condition.